南京地区汉族人群肥胖与前列腺癌的关系探讨  

Relationship between Obesity and Prostate Carcinoma of Han People in Nanjing Region

作　　者：胡潇[1] 宁松毅[1] 华立新[2] 卜强[1] 

机构地区：[1]江苏大学附属人民医院,江苏镇江212002 [2]南京医科大学第一附属医院,江苏南京210000

出　　处：《世界中西医结合杂志》2009年第4期277-279,共3页World Journal of Integrated Traditional and Western Medicine

摘　　要：目的探讨南京地区汉族人群肥胖与前列腺癌的关系。方法研究南京地区汉族人群的体重指数(BMI)与前列腺癌发病的关系,以及前列腺患者的BMI与血PSA浓度、病理学分级的关系。结果BMI与前列腺癌的发生风险无显著性差异;BMI与病理学分级在BMI=23.00～24.99组与BMI<23组相比有显著性差异(P=0.049);癌患者的BMI与血PSA在BMI=23.00～24.99组与BMI<23组相比较有显著性差异(P=0.031);在65岁～75岁,肥胖组前列腺体积明显大于非肥胖组,有显著性差异(P=0.037)。结论我国南京地区汉族人群的BMI与前列腺癌的发病无明显联系,且高BMI癌患者的血PSA浓度较体重正常人有所下降,而前列腺体积增大,造成活检率降低,将会影响对前列腺癌的早期诊断与治疗。Objective To explore the relationship between obesity and prostate carcinoma in Han people of Nanjing region.Methods It was to study the relationship between BMI and prostate carcinoma and the connection of BMI in prostate carcinoma patients with blood PSA concentration and pathological grade in Han people of Nanjing region.Results There was no correlation between BMI and the risk of prostate carcinoma.Significant difference in pathological grade presented between the group whose BMI varied from 23.00 to 24.99 and the group whose BMI less than 23 （P = 0.049）. Significant difference in PSA of carcinoma pa- tients presented in comparison between the group whose BMI varied from 23.00 to 24.99 and the group whose BMI less than 23 （ P = 0. 031 ）. In the group aged in the range from 65 to 75 years,the volume of prostate gland in obesity group was bigger apparently than those in non - obesity group, indicating significant difference statistically（ P = 0. 037 ）. Conclusion There is no significant correlation between BMI and the risk of prostate carcinoma in Han people of Nanjing region. Serum PSA level is lower in those prostate carci- noma patients with higher BMI compared with those with normal body mass. But the enlarged prostate volume results in reduced biopsy rate,which will impact the early diagnosis and treatment of prostate carcinoma.

关 键 词：肥胖 体重指数 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤] R394[医药卫生—临床医学]